Search / Trial NCT00001356

Characteristics of Mast Cells in Mastocytosis

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999

Trial Information

Current as of October 18, 2024

Completed

Keywords

Il 3 Stem Cell Factor Cytokines Cell Differentiation Receptors Bone Marrow Mastocytosis

Description

This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving therapy. Patients entered into the study are seen initially and may elect to be reevaluated yearly. The majority of patients to be entered into this protocol are currently followed at NIH on other protocols. Medical workup and treatment are in accordance with standard medical practice. The protocol is for 3 years, to be extended as facilities, faculty, and patients ...

Gender

ALL

Eligibility criteria

  • Subjects include children and adults from birth to 80 years of age.
  • Participants must have histologic evidence of an increased mast cell number in at least one organ system.
  • Must be willing to be seen at the NIH according to protocol guidelines.
  • Routine medical care must be available through their referral physician.
  • Patients with mastocytosis now followed at the NIH on protocol 88-I-0190 will be continued on this study.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0